All News
Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu
Robert B Chao, MD doctorRBC ( View Tweet)
Deucravacitinib TYK2i for PsA
Phase2b 16wk, Double-blind, Placebo, RCT
⬆️ACR20/50/70 response vs. PBO
⬆️HAQ-DI response, enthesitis resolution, MDA vs. PBO
*⃣No serious AE
@RheumNow #ACR20 Abs#L03 #ACRbest https://t.co/9Klu2aeEj2
Robert B Chao, MD doctorRBC ( View Tweet)
Deucravacitinib is a novel Tyrosine kinase 2 (TYK2) prev shown efficacy in psoriasis, now effective in PsA. PhII trial of 203 PsA patients showed wk 16 significant improvement in ACR20/50/70, enthesitis, SPARC scores. #ACR20 Abstr#L03 https://t.co/LGokmmlyrc
Dr. John Cush RheumNow ( View Tweet)
Abs#1562 Detected subclinical synovitis/tenosynovitis in 37.2% of PsA pts in clinical remission. Do you routinely use MRI to monitor disease activity in your PsA patients? @RheumNow #ACR20
Robert B Chao, MD doctorRBC ( View Tweet)
@rheumnow #acr20 #absL03 RCDB PC ph2 trial TYK2i Deucravacitinib for PsA: ACR 20 at 16wk 6 mg 52.9% & 12 mg 62.7% vs PBO 31.8%. csDMARD & TNFi failure included. no serious infections, herpes zoster, opportunistic infections, or thrombotic events https://t.co/WVm4llPv5i
Olga Petryna DrPetryna ( View Tweet)
No need to stop Tofa w/the flu?
👉Posthoc analysis 7964 Tofa pts over 14-15 flu seasons reported similar flu rates compared to ADA, MTX, PCB.
👉Tofa cont. in 70% pts; 28.8% stopped; mean days to resolution similar.
Abstr#L04 #ACR20 @rheumnow #ACRBest
https://t.co/rZXKRVl7uK
k dao KDAO2011 ( View Tweet)
#Curcumin for PsA & RA?🤔
Results suggest curcumin's efficacy on pt's perceived symptom alleviation & poss correlation w/ dose and length of tx. @RheumNow #ACR20 abs1230 https://t.co/xUxUEW02ww
sheila RHEUMarampa ( View Tweet)
Lots of interesting studies in Spondyloarthritis including AxSpA and PsA at #ACR20 @RheumNow https://t.co/tIyqyMdmTf
Dr. Antoni Chan synovialjoints ( View Tweet)
PsA still has ^mortality vs general marched pop’n. Can we do better for our pts? Abstr#1476 @RheumNow @CRASCRRheum #ACR20 https://t.co/aDkTF9dFF0
Janet Pope Janetbirdope ( View Tweet)
When do you tend to change tx strategies in PsA? #ACR20 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Despite 30% decrease in mortality over the past 2 decades, the mortality gap remains in psoriasis and #PsA. #ACR20 Abstract #1476 by @Keith_Colaco. @NPF @WCRInstitute @researchuoft @RheumNow @rheum_cat https://t.co/CXTELMJh8P
Lihi Eder lihi_eder ( View Tweet)
#Multimorbidity in #RheumaticDisease: Abs#1466:
-Highly prevalent across RA, PsA, gout & OA
-Highest burden in #gout
Important study highlighting need to recognise burden of MM in #rheumatology patients for holistic optimised management.
#ACR20 @RheumNow
https://t.co/esinnHoUME https://t.co/bApXfx7hOU
Mrinalini Dey DrMiniDey ( View Tweet)
Dr England presents on multimorbidity in RA, PsA, gout, and OA within RISE registry. Highly prevalent in all 4 but most pronounced in gout and RA. Critical to recognise and manage. @rheumnow #ACR20 Abstr#1466 https://t.co/XtwIfJnVXV
Richard Conway RichardPAConway ( View Tweet)
Are there distinct groups of axSpA and PsA patients with peripheral arthritis. This study shows heterogeneous patterns of peripheral involvement and overlap in SpA and PsA groups @RheumNow #ACR20 Abstr#1311 https://t.co/2Q5FH6ZrWm
Dr. Antoni Chan synovialjoints ( View Tweet)
Wanna learn about T2T PsA abstracts from #ACR20? Here are my highlights! @RheumNow https://t.co/0X7FF3rwTz
Dr. Rachel Tate uptoTate ( View Tweet)
SELECT-PsA Phase 3, Placebo, Active controlled trial of Upadacitinib in PsA
1⃣UPA 15mg or 30mg - ⬆️PROs vs. Placebo thru 24wks
2⃣Similar improvement in UPA 15mg vs. 30mg
3⃣Both doses similar or > Adalimumab
@RheumNow #ACR20 Abs#1341 #ACRbest https://t.co/yu9IEX8tf0
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR20👀🔥🔥@AliDuarteMD Population epi revealed:
⭐️Markedly increased SLE incidence
⭐️Drastically increased SLE prevalence
Better epi saves 🫀, saves💰, informs better🧪🔬and💉🩺@RheumNow @LupusOrg @LupusResearch https://t.co/CTzJuB9DVk
Yu (Ray) Zuo RayZuoMD ( View Tweet)
NT-proBNP and TnI predicted cardiovascular events in patients with PsO or PsA. Abs#1328
Do you measure/monitor for cardiovascular disease in your psoriatic patients?
@RheumNow #ACR20
Robert B Chao, MD doctorRBC ( View Tweet)
UPA was efficacious in treating axial symptoms in pts with PsA. #ABS1372 #ACR20 @RheumNow https://t.co/ut6L0jM9WJ https://t.co/6H2N3ap6eI
Dr. Rachel Tate uptoTate ( View Tweet)
Shifting Treatment Paradigms in Psoriatic Arthritis: Dr. Eric Ruderman (@JointMD)
Chicago-based Dr. Eric Ruderman discussed the shifting treatment paradigms in psoriatic arthritis by reviewing abstracts #0504 and #2026 at #ACR20.
https://t.co/jsLkgWG63v https://t.co/h3r2oapOij
Links:
Dr. John Cush RheumNow ( View Tweet)
